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ABSTRACT 
Ketamine has shown effectiveness as a rapid-acting antidepressant with antisuicidal 
effects in terms of reduction of suicidal ideation in the short term. However, the evidence 
for long-term maintenance ketamine therapy for treatment-resistant depression (TRD) 
and suicidal behavior is limited. This case series (N=13) highlights the role of adjunctive 
serial maintenance ketamine infusions in restoring functionality in treatment-resistant 
unipolar and bipolar (mixed) depression with significant suicide risk and multiple 
comorbidities, including alcohol dependence. Two cases of TRD achieved functional 
remission with long-term maintenance ketamine treatment. The first case illustrates the 
potential synergistic interaction between ketamine and lamotrigine to achieve a sustained 
antidepressant response in the patient for 7 months. The second case may possibly be 
the longest reported case of maintenance ketamine therapy, with treatment continuing 
for 5 years to date. Ketamine treatment showed acute effectiveness in another 7 cases, 
especially in terms of reduction of suicidal ideation, albeit without significant long-term 
antidepressant effect. Factors that may contribute to lack of effectiveness of serial 
ketamine include inadequate mood stabilization in TRD in bipolar spectrum diagnoses, 
concomitant benzodiazepine use, complex comorbidities, and adverse effects such as 
significant hypertension and severe dissociation. Future systematic controlled studies are 
warranted to establish the efficacy and safety profile of long-term ketamine as 
maintenance therapy for TRD with suicidal behavior. 
